|
|
| (8 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Dabigatran]] |
| |authorTag={{SS}}
| |
| |genericName=Dabigatran etexilate mesylate
| |
| |aOrAn=an
| |
| |drugClass=Anti-coagulant
| |
| |indication=reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=Esophagitis, Gastritis, Gastroesophageal reflux disease, Gastrointestinal hemorrhage Gastrointestinal ulcer, Indigestion, Bleeding
| |
| |blackBoxWarningTitle=DISCONTINUING PRADAXA IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (iscontinuing PRADAXA places patients at an increased risk of thrombotic events. If anticoagulation with PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.)
| |
| |fdaLIADAdult=<h4>Condition 1</h5>
| |
| | |
| * Dosing Information
| |
| | |
| :: (Dosage)
| |
| }}
| |